<DOC>
	<DOCNO>NCT01844973</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics safety M518101 male female plaque psoriasis patient .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics Safety M518101 Plaque Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Who able willing give sign informed consent Who male female age 18 year old plaque psoriasis confirm Investigator . Who â‰¥20 % body surface area ( BSA ) afflict plaque Who neither pregnant breastfeeding , plan become pregnant study . Who history allergy vitamin D3 derivative preparation history relevant drug hypersensitivity . BMI &gt; 32.0 kg/m2 Who pregnant lactate . Who renal hepatic insufficiency , clinically significant cardiac , renal hepatic disease . Who deem eligible determined medical history , physical examination clinical laboratory safety test . Who clinically relevant history presence disease surgical history psoriasis likely affect conduct study . Whose serum calcium level exceed upper limit reference range Who use investigational medicinal product and/or participate clinical study within 60 day randomization . Who take durg know effect calcium metabolism within 30days randomization Who treat drug know risk QT prolongation within 30days randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>